Loading
Every dated change on the records linked to Essential thrombocythaemia (ET), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Composite of thrombosis, serious haemorrhage or vascular death more frequent with anagrelide (odds ratio 1.
A milestone in how this cancer is treated.
In 809 high-risk patients hydroxyurea plus aspirin gave fewer arterial clots, less bleeding and less progression to myelofibrosis than anagrelide plus aspirin.